Better Context → Better Decisions
Context counts in life sciences. The FENIX analyst team is tirelessly using its experience to put you in a position to succeed. Below, our readers without corporate access will find a wealth of contextualized life science insight ready to be purchased in the FENIX Marketplace. If our content sharing limitations are inconvenient for you, reach out to Brady for unlimited corporate, institutional, or individual access.
$599
Posted in: DPP-IVi, Glucose Monitoring, Other Aug 09 | 2022FDA Detects Impurities in Samples of Merck’s Januvia; Senseonics and Ionis Q2 ’22 Earnings UpdatesPurchase Blast$599
Posted in: Basal Insulin, Other Aug 08 | 2022Gan & Lee GZR4 IND Granted FDA Clearance; Viatris Q2 ’22 Earnings UpdatePurchase Blast$599
Posted in: Basal Insulin, GLP-1RA, Other Aug 05 | 2022Novo Q2 ’22 London Earnings; Vertex and Amgen Q2 ’22 Earnings UpdatesPurchase Blast$599
Posted in: Glucose Monitoring, Insulin Delivery, Other Aug 04 | 2022Insulet, Provention Bio, Bayer, and Regeneron Q2 ‘22 Earnings Updates; Abbott Partners with WeightWatchersPurchase Blast$599
Posted in: Basal Insulin, Dual/triple agonist, Insulin Delivery, Other Aug 04 | 2022Mounjaro Off to an Impressive Start; Lilly Q2 ’22 Earnings UpdatePurchase Blast$599
Posted in: Insulin Delivery, Other Aug 04 | 2022Tandem, Amarin, and Intercept Q2 ’22 Earnings Updates; Anthem to Cover Eversense E3 Implantable CGMPurchase Blast$599
Posted in: GLP-1RA, Other Aug 03 | 2022SELECT Doesn’t Stop at Interim Analysis; Novo Nordisk Q2 ’22 Earnings UpdatePurchase Blast$599
Posted in: GLP-1RA, Glucose Monitoring, Other, SGLT2i Aug 02 | 2022Lexicon Q2 ’22 Earnings Update; CLEAR Outcomes CVOT Reaches 100% MACE Accumulation; Esperion Q2 ’22 Earnings Update; Dexcom ONE Available with Prescription in UK; Gan & Lee Dose First Patient in Ph2 GZR18 Trial for T2DM; Structure Therapeutics Advances Diabetes & Obesity Clinical ProgramPurchase Blast$599
Posted in: Basal Insulin, Bolus Insulin, Insulin Delivery, Other Aug 01 | 2022Insulet Initiates Omnipod 5 US Broad Launch; Arecor Buys Tetris Pharma; Sanofi/Optum Partner for Insulin AffordabilityPurchase Blast$599
Posted in: Basal Insulin, Other, SGLT2i Jul 29 | 2022Novo’s QW Insulin Icodec Meets Primary Endpoints in ONWARDS 3 and 4; AZ and Alnylam Q2 ’22 earnings updates; Better Therapeutics Meets Secondary Endpoint in BT-001 Pivotal Trial in T2DMPurchase Blast$599
Posted in: Basal Insulin, GLP-1RA, Glucose Monitoring, Other Jul 29 | 2022Dexcom G7 Delayed in US; Dexcom, Pfizer, Biocon, Sanofi, and Teladoc Q2 ’22 Earnings UpdatesPurchase Blast$599
Posted in: SGLT2i Jul 27 | 2022Lexicon’s Sota HF NDA Accepted by FDA in Patients With and Without T2DMPurchase Blast$599
Posted in: Basal Insulin, Other Jul 27 | 2022vTv Receives $10M Investment from CinPax, LLC; Oramed Reaches 50% Enrollment in Second Ph3 Oral Insulin Trial; Esperion Establishes Scientific Advisory BoardPurchase Blast$599
Posted in: Dual/triple agonist, GLP-1RA, Insulin Delivery Jul 22 | 2022Tandem Acquires Capillary Biomedical; Lilly’s Mounjaro Receives Positive CHMP OpinionPurchase Blast$599
Posted in: Basal Insulin, Glucose Monitoring, Insulin Delivery, Other Jul 20 | 2022Abbott Q2 ’22 Earnings Update; Lilly to Initiate Fourth Trial in Ph3 QWINT Program; Ionis’s Ph3 Lp(a) HORIZON CVOT Completes EnrollmentPurchase Blast$599
Posted in: Basal Insulin, Bolus Insulin, Dual/triple agonist Jul 19 | 2022Tirzepatide up for CHMP Opinion; July 18-21 CHMP Agenda; Lilly Initiates QW Insulin T2DM MDI Trial (QWINT-4); UHC Eliminates Insulin OOP CostsPurchase Blast$599
Posted in: Glucose Monitoring, Insulin Delivery, Other Jul 18 | 2022Abbott Progresses Libre 3 US Launch; New Trial Dasiglucagon Trial for Inreda’s Bi-hormonal AID system; NICE Recommends Amarin’s Vazkepa for Reimbursement in England and WalesPurchase BlastGet the Latest Analysis
Stay informed and aligned with frequent updates to keep a pulse on the industry.
If you already have an account, please log in. If you have any questions or would like to subscribe to our services, please contact Brady.